One Stem Cell Generates 14 Million Cancer-Fighting Immune Cells—A Game-Changer for NK Cell Therapy

Scientists in China have developed a breakthrough method to mass-produce natural killer (NK) cells for cancer treatment by engineering stem cells from cord blood rather than modifying mature immune cells. The new approach generates up to 14 million tumor-fighting NK cells from a single stem cell, with the potential to create thousands of treatment doses from one cord blood unit while significantly reducing production costs.

What Are Natural Killer Cells and Why Do They Matter for Cancer?

Natural killer cells are part of your body's frontline defense against cancer and viruses. Unlike other immune cells that need specific training to recognize threats, NK cells have an innate ability to detect and destroy abnormal cells on their own. This makes them an attractive tool for cancer immunotherapy. In a specialized approach called CAR-NK therapy, scientists equip these cells with a lab-designed receptor (called a CAR, or chimeric antigen receptor) that acts like a targeting system, allowing the cells to recognize specific markers on cancer cells and attack them with precision.

How Does the New Stem Cell Approach Improve on Traditional Methods?

Traditional CAR-NK therapies have relied on collecting and modifying mature NK cells from sources like peripheral blood or cord blood. This approach comes with significant limitations: the cells vary widely from person to person, genetic modification is inefficient, production costs are high, and the entire process takes a long time. Researchers at the Institute of Zoology of the Chinese Academy of Sciences, led by Prof. Wang Jinyong, took a different approach by starting earlier in the cell development process.

Instead of modifying mature NK cells, the team worked with CD34+ hematopoietic stem and progenitor cells (HSPCs)—early-stage cells taken from cord blood. They then guided these cells to develop into induced NK (iNK) cells and CAR-engineered iNK (CAR-iNK) cells. By moving the genetic engineering step to this earlier developmental stage, the researchers overcame the efficiency and maturity problems that had plagued previous cord blood approaches.

Steps to Understanding the Three-Stage Production Process

• Stage One—Expansion: CD34+ HSPCs (or CAR-modified versions) were cultured with irradiated AFT024 feeder cells, causing them to multiply roughly 800- to 1,000-fold within 14 days, creating a massive population of progenitor cells ready for the next phase.
• Stage Two—Commitment: The expanded cells were then cultured with OP9 feeder cells to create artificial hematopoietic organoid aggregates, specialized structures that guide the cells to commit to becoming NK cells and support their efficient development.
• Stage Three—Maturation: Cells that had committed to the NK lineage were allowed to mature and multiply further, producing highly pure iNK or CAR-iNK cells that expressed the CD16 marker needed for tumor-killing function.

What Are the Concrete Numbers Behind This Breakthrough?

The results are striking. A single CD34+ HSPC can generate as many as 14 million iNK cells or 7.6 million CAR-iNK cells. The researchers estimate that just one-fifth of a typical cord blood unit could theoretically yield enough cells for thousands or even tens of thousands of treatment doses. This scalability is transformative for a field where cell scarcity and cost have been major barriers.

Another dramatic improvement involves the viral vector—the delivery vehicle used to insert the CAR gene into cells. The new method requires only about 1/140,000 to 1/600,000 as much viral vector compared with the amount typically needed to modify mature NK cells. This reduction in viral material not only lowers costs but also reduces potential side effects associated with viral vectors.

How Effective Are These Engineered Cells Against Cancer?

In laboratory testing, both iNK and CAR-iNK cells demonstrated powerful tumor-killing ability. When researchers tested CD19 CAR-iNK cells in mouse models of human B-cell acute lymphoblastic leukemia (B-ALL)—a blood cancer—the engineered cells reduced tumor growth and extended the animals' survival. These results suggest the approach could translate to human patients, though clinical trials would be needed to confirm safety and efficacy.

The research was published in Nature Biomedical Engineering and was supported by the Ministry of Science and Technology of the People's Republic of China and the National Natural Science Foundation of China, along with other funding sources. The findings represent a significant step forward in making NK cell immunotherapy more practical, affordable, and accessible for cancer patients worldwide.